FZMD
Fuse Medical, Inc.0.0700
+0.0000+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
5.17MP/E (TTM)
1.40Basic EPS (TTM)
0.05Dividend Yield
0%Recent Filings
8-K
Fuse deregisters stock voluntarily
Fuse Medical filed a Form 15 on September 27, 2023, to voluntarily deregister its common stock and suspend SEC reporting obligations. The board cited high compliance costs outweighing benefits, amid stock undervaluation and low trading volume, aiming to slash expenses and refocus on core medical device operations. Deregistration frees management from quarterly distractions. Yet, the company will share annual statements with OTC Pink to keep FZMD trading.
8-K
Q2 profit surges 7% on revenue
Fuse Medical swung to a $307,588 net profit for Q2 2023, up from a $322,936 loss last year, fueled by 7% revenue growth to $5.0 million and a 31% gross profit jump to $3.5 million at 69% margins. Strategic pushes into branded products and national distribution drove the turnaround, while SG&A rose modestly to $1.6 million. Growth accelerates. Forward plans target new orthopedic launches through 2024, but integration risks linger.
10-Q
Q2 FY2023 results
Fuse Medical swung to an operating profit of $368,859 in Q2 ended June 30, 2023, up from a $281,238 loss a year earlier, while YTD operating income hit $203,283 versus a $719,823 loss (derived). Revenue climbed 7% y/y to $4.99M in the quarter on higher prices per case, though YTD dipped 3% to $8.98M; gross margins expanded to 69% from 57% y/y, fueled by more Fuse-branded sales that cut costs 25% to $1.53M. Diluted EPS held at $0.00 on 78M shares, with no anti-dilution flagged. Cash rose to $253K on $232K operating inflows, revolver draw at $1.87M under a $5M facility maturing 2025 with covenants met via amendments; free cash flow not disclosed in the 10-Q. The earn-out liability from the 2017 CPM acquisition stayed flat at $7.49M. Yet customer concentration risks linger, with one buyer at 19% of YTD revenue.
8-K
Annual meeting results
Fuse Medical held its 2023 Annual Meeting on June 23, with 64.5 million shares present, meeting quorum. Shareholders elected Renato V. Bosita, Jr., MD, Mark W. Brooks, Lawrence S. Yellin, and Christopher C. Reeg as directors for one-year terms, each garnering over 63 million votes for. They ratified M&K CPAs, PLLC as auditors for the fiscal year ending December 31, 2023, with 64.5 million in favor. Routine governance upheld.
10-Q
Q1 FY2023 results
Fuse Medical's Q1 2023 results showed revenue dipping 13% year-over-year to $3.98M, driven by lower retail sales prices per case, yet gross profit held steady at $2.82M with margins expanding to 71% from 62% thanks to more Fuse-branded products cutting costs. Operating loss narrowed to $166K from $439K, while net loss improved 52% to $228K, mainly from reduced commissions and cost efficiencies, though interest rose on higher rates. Cash climbed to $211K, bolstered by $331K in operating cash flow, with revolver debt down to $1.73M under a $5M facility maturing January 2025 at prime plus 1.75%, and recent covenant waivers aiding liquidity. No free cash flow disclosed in the 10-Q. Steady amid pricing pressures.
GMED
Globus Medical, Inc.
85.79-0.71
IRME
IR-Med Inc.
0.02-0.01
KIDS
OrthoPediatrics Corp.
17.91-0.08
MDNC
MEDINOTEC INC
5.00+0.00
OFIX
Orthofix Medical Inc.
15.55-0.16
PFSA
Profusa, Inc.
0.11-0.01
SIBN
SI-BONE, Inc.
19.42+1.01
TNON
Tenon Medical, Inc.
1.10+0.02
XTNT
Xtant Medical Holdings, Inc.
0.73+0.04
ZBH
Zimmer Biomet Holdings, Inc.
90.91-1.52